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would predict a good long-term outcome. If it is indeed true that
the vast majority (perhaps even all) of individuals achieving SVRs
were destined not to develop long-term complications of liver
disease, it would follow that SVRs would be associated with
non-progressive disease but that antiviral therapy may not pro-
vide overall beneﬁt to the treated group.
To validate the SVR as a surrogate outcome, RCTs in the future
should compare patients treated with regimens that result in lar-
ger percentages of SVRs (e.g., 90%) to untreated patients and
employ clinical events as the primary outcome. If patients in pre-
vious RCTs did not subsequently receive additional treatment, we
would encourage the authors of those trials to assess the long-
term clinical outcomes retrospectively. As of this time, treatment
advocates are supporting treatment that has no level 1 (well
designed and executed RCTs) evidence for improved clinical out-
comes, but is costly and toxic (including occasional mortal).
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Letters to the EditorReply to: ‘Evidence recommending antiviral therapy in hepatitis C’To the Editor:
We thank Dr. Koretz and colleagues for responding to our apprai-
sal of their Cochrane meta-analysis [1,2], The discussion on the
clinical beneﬁts of antiviral therapy for chronic hepatitis C virus
(HCV) infection is important because physicians should be aware
of the strengths of current evidence as well as of the remaining
uncertainties.
Koretz et al. again highlight and explain that sustained viro-
logical response (SVR) is not a validated surrogate marker as sub-
stantial proof from randomized placebo-controlled trials that
antiviral therapy improves clinical outcome is lacking. As was
clearly discussed in our recent review, this is correct. We also
mentioned that the repeatedly found association between SVR
and reduced cirrhosis-related morbidity and mortality might
potentially be subject to residual confounding. Indeed, this possi-
bility cannot be excluded in the performed cohort studies. How-
ever, in light of the extensive multivariate analyses in which SVR
remained the most important factor associated with beneﬁcial
clinical outcome, we agree with others that it is hard to think
of a confounder which would completely annihilate this associa-
tion [3–5].
While recognizing that the possibility of residual confounding
remains a scientiﬁc limitation, we have indeed challenged the
1102 Journal of Hepatology 20
Open access under CC BY-NC-ND license.statement that no kind of antiviral therapy can currently be advo-
cated. One of the key arguments by which Koretz et al. try to sub-
stantiate this statement is the increased mortality rate among
interferon-treated patients as compared to controls, which was
observed in their meta-analysis. However, it should be clearly
mentioned that this was only found in the extended follow-up
analyses of the Hepatitis C Antiviral Long-term Treatment
Against Cirrhosis (HALT-C) trial, which almost solely drove their
meta-analyses on SVR and mortality [6]. Unfortunately, in their
response letter, Koretz et al. do not share their thoughts on the
fact that all controls in the HALT-C study received a regular pegy-
lated interferon (PegIFN) and ribavirin treatment course just prior
to randomization. Consequently, this study compared long-term
PegIFN therapy to short-term PegIFN therapy rather than to no
treatment [7]. The design of the HALT-C trial thus prohibits
extrapolation of the increased mortality rate as observed with
long-term maintenance therapy to the regular PegIFN regimens.
Therefore, this study should not have been included in the
meta-analyses.
Our review did discuss that patients treated with interferon
and ribavirin combination therapy had a beneﬁcial clinical out-
come as compared to patients treated with interferon mono ther-
apy. In fact, as the improved clinical outcome is in line with the14 vol. 60 j 1097–1103
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improved SVR rate of combination therapy, we consider this to be
another argument to strengthen our case. However, we acknowl-
edge that the number needed to treat (NNT) to prevent cirrhosis-
related events with these earlier interferon-based regimens was
high. Awareness of this alternative measure of treatment efﬁcacy
is desired, especially when considering the cost-beneﬁt ratio of
new treatment regimens or the allocation of limited treatment
resources. Based on our analyses among patients with HCV geno-
type 1 infection and cirrhosis, we have recently described the
enormous decline in the NNT to prevent cirrhosis-related mor-
bidity or mortality with the development of antiviral therapy
over the last two decades [8].
Indeed, there is limited data available to assess the validity of
SVR as surrogate endpoint, especially considering that trials
assessing long-term low-dose PegIFN should be excluded. How-
ever, when validation of SVR is aimed, restriction to interferon
mono therapy in treatment experienced patients is not needed
Still, randomized placebo-controlled trials on clinical endpoints
are scarce and new trials, which might be able to settle this dis-
cussion, are unlikely to be executed. Recently, several phase 3
clinical studies showed SVR rates around 95% with 8–12 weeks
of well-tolerated interferon-free regimens. These high response
rates were independent of baseline characteristics, thereby
excluding the unlikely possibility that we are only able to cure
patients with a benign natural course of disease. First clinical data
already suggest that viral suppression/eradication with these reg-
imens is linked to an over proportionate treatment-related
improvement in clinical outcome [9,10]. We are convinced that
in particular among patients with advanced liver disease, long-
term follow-up assessment of these treated patient populations
will further conﬁrm the strong link between SVR and reduced
mortality.
The data clearly show that treatment increases the rate of
SVR. Although it is only now that data are emerging to validate
the clinical importance of this longstanding and robust surrogate
endpoint, we consider it to be unethical to generally withhold
treatment and perform randomized studies, in which many
patients are denied a good chance to eradicate their HCV infec-
tion, in order to conﬁrm the well-supported and biologically
plausible causal relation between SVR and improved clinical
outcome.
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